Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The consumption of antibiotics has increased significantly over the past 15 years, according to a recent study. The increase occurred despite the international push to reduce the use of these important drugs.

Researchers found that while many low- and middle-income countries still lack appropriate access to antibiotics, the global increase was driven largely by some developing countries which face more drug-resistant infections and a lack of tools to test infections and track how these medications are used.

To tackle antimicrobial resistance (AMR), we need to look at all the factors behind how and when antibiotics are used. One obstacle I often see as a medical microbiologist working in developing countries, is a lack of access to clean water, which makes preventing and controlling infections nearly impossible. It is a major driver of inappropriate antibiotic use and, ultimately, the growth in antibiotic-resistant bugs – so-called “superbugs”.

Read the full article on The Conversation website, written by Abhilasha Karkey (Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine). 

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.